Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Acquired by Creative Planning

Creative Planning lifted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 24.6% in the second quarter, HoldingsChannel.com reports. The firm owned 11,520 shares of the biopharmaceutical company’s stock after acquiring an additional 2,276 shares during the quarter. Creative Planning’s holdings in Agios Pharmaceuticals were worth $497,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of AGIO. Caxton Associates LP boosted its holdings in Agios Pharmaceuticals by 0.7% during the 2nd quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock valued at $1,615,000 after acquiring an additional 264 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Agios Pharmaceuticals by 0.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock valued at $1,148,000 after acquiring an additional 314 shares during the period. CANADA LIFE ASSURANCE Co boosted its stake in shares of Agios Pharmaceuticals by 1.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock valued at $911,000 after buying an additional 540 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at about $37,000. Finally, Quest Partners LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at about $40,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on AGIO shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, August 5th. Leerink Partners lowered Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Raymond James reaffirmed an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Finally, Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $52.20.

Agios Pharmaceuticals Stock Down 3.2 %

Shares of NASDAQ AGIO opened at $41.28 on Tuesday. Agios Pharmaceuticals, Inc. has a fifty-two week low of $19.80 and a fifty-two week high of $53.28. The business has a 50 day moving average price of $44.57 and a two-hundred day moving average price of $40.74. The firm has a market cap of $2.34 billion, a PE ratio of -6.53 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The firm had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. Agios Pharmaceuticals’s revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.51) EPS. On average, analysts anticipate that Agios Pharmaceuticals, Inc. will post -4.87 earnings per share for the current year.

Insider Transactions at Agios Pharmaceuticals

In other news, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the sale, the chief executive officer now owns 78,792 shares in the company, valued at $3,368,358. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares of the company’s stock, valued at $988,346.74. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brian Goff sold 11,091 shares of the stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at approximately $3,368,358. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.